☆ 4.6 Letter

2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification

JOURNAL OF THORACIC ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification

Jennifer L. Sauter et al.

Summary: The 2021 WHO Classification of Tumors of the Pleura and Pericardium has made substantial changes compared to the 2015 classification. These changes include the merging of pleural and pericardial tumors, renaming of certain tumor types, elimination of certain terms, addition of new classification categories, incorporation of new prognostic features, introduction of grading system, and identification of useful immunohistochemical markers.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Heart

Joseph J. Maleszewski et al.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

Alexander Marx et al.

Summary: This article provides an overview of the new developments in the fifth edition of the WHO classification of thymic epithelial tumors, mediastinal germ cell tumors, and mesenchymal neoplasms, focusing on diagnostic, molecular, and conceptual advances. Diagnostic advances include immunohistochemical characterization and the identification of genetic translocations. Molecular and tumor biological advancements include the finding that thymomas and most thymic carcinomas lack currently targetable mutations, but typically have a PD-L1(high) phenotype. Additionally, conceptual advancements for the classification of thymic NETs are discussed.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Andrew G. Nicholson et al.

Summary: The 2021 WHO Classification of Thoracic Tumours focuses on the application of genetics and molecular pathology, providing specific classifications and diagnostic criteria for various tumors, while emphasizing new tumor features and concepts.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Reprint of Introduction to 2021 WHO Classification of Thoracic Tumors

Ming-Sound Tsao et al.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease

Anna Michelotti et al.

Summary: Standard treatment for advanced non-small cell lung cancer (NSCLC) traditionally involved systemic chemotherapy, but precision medicine has led to a revolutionary change in the therapeutic landscape. The discovery of oncogenic driver mutations in genes like EGFR, ALK, and ROS1 has identified a subset of patients who benefit greatly from targeted therapies. However, there is still an urgent clinical need to find new potential driver mutations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Editorial Material Oncology

The WHO Classification of Haematolymphoid Tumours

Ian A. Cree

LEUKEMIA (2022)

添加到收藏夹

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

添加到收藏夹

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

添加到收藏夹

Letter Oncology

Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer

Manana Javey et al.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article

CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW

M. Kumar et al.

Experimental Oncology (2022)

添加到收藏夹

Article Oncology

Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer

David M. Hwang et al.

Summary: PD-L1 expression rates vary in different subgroups of NSCLC patients, with higher expression in certain tumor types and stages. There is moderate concordance between biopsy and resection specimens for PD-L1 testing, but discordance rates are higher in smaller biopsy samples. Biopsy of metastatic sites may increase the proportion of patients with high PD-L1 expression.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Review Pathology

Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System

David M. Meredith

ADVANCES IN ANATOMIC PATHOLOGY (2020)

添加到收藏夹

Editorial Material Oncology

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Review Oncology

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2011)

添加到收藏夹

Article Oncology

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Toshimi Takano et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.